TY - JOUR
T1 - Telemedicine in Oncology and Reimbursement Policy During COVID-19 and Beyond
AU - Kircher, Sheetal M.
AU - Mulcahy, Mary
AU - Kalyan, Aparna
AU - Weldon, Christine B.
AU - Trosman, Julia R.
AU - Benson III, Al B
N1 - Publisher Copyright:
© JNCCN—Journal of the National Comprehensive Cancer Network.
PY - 2021/3
Y1 - 2021/3
N2 - The first confirmed case of coronavirus disease 2019 (COVID-19) in the United States was reported on January 20, 2020. As of September 17, 2020, there were more than 6.6 million confirmed cases and 196,277 deaths. Limited data are available on outcomes of immunocompromised patients, but early published reports from China indicate that those with cancer have a 3.5 times higher risk of ICU admission, mechanical ventilation, or death than those without cancer. Because of the uncertain behavior of COVID-19, it has become imperative for practices to limit exposure to vulnerable patients. Telemedicine has been one of the cornerstones of caring for patients with cancer during the COVID-19 pandemic. This review provides an overview of reimbursement policy by public and private payers before and during the COVID-19 pandemic, describes implications in cancer care, and offers considerations for future reimbursement policy.
AB - The first confirmed case of coronavirus disease 2019 (COVID-19) in the United States was reported on January 20, 2020. As of September 17, 2020, there were more than 6.6 million confirmed cases and 196,277 deaths. Limited data are available on outcomes of immunocompromised patients, but early published reports from China indicate that those with cancer have a 3.5 times higher risk of ICU admission, mechanical ventilation, or death than those without cancer. Because of the uncertain behavior of COVID-19, it has become imperative for practices to limit exposure to vulnerable patients. Telemedicine has been one of the cornerstones of caring for patients with cancer during the COVID-19 pandemic. This review provides an overview of reimbursement policy by public and private payers before and during the COVID-19 pandemic, describes implications in cancer care, and offers considerations for future reimbursement policy.
UR - http://www.scopus.com/inward/record.url?scp=85140098731&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85140098731&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2020.7639
DO - 10.6004/jnccn.2020.7639
M3 - Article
C2 - 32998106
AN - SCOPUS:85140098731
VL - 19
SP - 11
EP - 17
JO - Journal of the National Comprehensive Cancer Network : JNCCN
JF - Journal of the National Comprehensive Cancer Network : JNCCN
SN - 1540-1405
IS - 13
ER -
